M&A

Following the acquisition, it is intended that Zanovex will own the trademarks, marketing authorisations and licence manufacturing information for both Alimta, a chemotherapy drug for the treatment of certain types of non-small cell lung cancer and malignant pleural mesothelioma, and Cialis, a men’s health product for the treatment of erectile dysfunction.

The press release explains that: ‘ZP Therapeutics, the commercial division of Zuellig Pharma, will promote the two brands in the relevant markets. Prior to the acquisition, ZP Therapeutics was responsible for the promotion and distribution of the brands as part of a broader, long-term strategic partnership with Lilly in Brunei, Indonesia, Malaysia, Philippines and Thailand’.

John Graham, group CEO at Zuellig Pharma, commented: “This acquisition marks a major milestone in the evolution of Zuellig Pharma to becoming an integrated healthcare solutions company. It demonstrates the increasing strength of ZP Therapeutics, which has extensive in-market expertise and capabilities in driving growth of healthcare products in Asia. We look forward to further expanding our commercial presence in the region through meaningful strategic partnerships with the world’s leading biopharma companies as we remain focused on our purpose of making healthcare more accessible to communities in Asia.”